Literature DB >> 3691450

A mathematical model of the penetration of polycyclic aromatic hydrocarbons through the bronchial lining layer.

P Gerde1, P Scholander.   

Abstract

The enhanced carcinogenicity of particle-associated polycyclic aromatic hydrocarbons (PAHs) has previously been explained by their prolonged retention in the lung due to the slow release of these substances from their carrier particles. However, the mathematical model presented here indicates that the lipid-aqueous heterogenic structure of the bronchial lining layer (BLL) in itself may constitute the major rate-determining step in the overall transport of PAHs from carrier particles to the bronchial epithelium. Conditions within the BLL are then as important for the resulting cellular burdens of PAHs in the lung as are the properties of the carrier particles for these hydrocarbons. Thus, in addition to other vital functions in the respiratory tract, the lipids in lung surfactant can also be important in protecting the lung from the action of lipophilic carcinogens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691450     DOI: 10.1016/s0013-9351(87)80241-4

Source DB:  PubMed          Journal:  Environ Res        ISSN: 0013-9351            Impact factor:   6.498


  3 in total

1.  Adsorption of benzo(a)pyrene on to asbestos and manmade mineral fibres in an aqueous solution and in a biological model solution.

Authors:  P Gerde; P Scholander
Journal:  Br J Ind Med       Date:  1988-10

2.  Mass transfer rates of polycyclic aromatic hydrocarbons between micron-size particles and their environment--theoretical estimates.

Authors:  P Gerde; P Scholander
Journal:  Environ Health Perspect       Date:  1989-02       Impact factor: 9.031

3.  Use of PBPK Modeling To Evaluate the Performance of Dissolv It, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products.

Authors:  Mireille Hassoun; Maria Malmlöf; Otto Scheibelhofer; Abhinav Kumar; Sukhi Bansal; Ewa Selg; Mattias Nowenwik; Per Gerde; Snezana Radivojev; Amrit Paudel; Sumit Arora; Ben Forbes
Journal:  Mol Pharm       Date:  2019-02-15       Impact factor: 4.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.